Patently-O

APRIL 28, 2022

Eli Lilly and Company , 598 F.3d I would love to hear your thoughts on this topic. The court in Ariad explained that a “a vague functional description” may be insufficient as it likely describes the unpatentable problem rather than a patentable solution. Ariad Pharmaceuticals et al. 3d 1336 (Fed. 2010) (en banc).

Inventor 105

Inventor Invention Art Litigation 105

SpicyIP

JULY 11, 2021

Topical Highlight. I analysed Bajaj Healthcare’s application for compulsory license to manufacture Eli Lilly’s Baricitinib, an arthritis drug more recently used for Covid treatment. IPAB Issue Finally Comes to a Conclusion: Delhi HC Creates Specialist IP Division.

Moral Rights 105

Moral Rights Journalism Licensing IP 105

Patently-O

NOVEMBER 11, 2022

The scope afforded to chemical genus claims under 35 USC § 112(a)’s enablement and written description requirements has been hot topic recently (at least in certain quarters).

Inventor 49

Inventor Invention Patent Reporting 49

Fish & Richardson Trademark & Copyright Thoughts

JANUARY 11, 2022

Eli Lilly). The letter discusses the BPCIA and the Hatch-Waxman Act frameworks (for small molecule drugs) and sets forth several topics for USPTO’s consideration and further discussion: engagement between FDA and USPTO to increase efficiencies, possible misuse of the patent system (e.g., See Eli Lilly & Co.

Litigation 52

Litigation Settlement Patent Marketing 52

SpicyIP

DECEMBER 30, 2023

As in previous years, we have divided these developments into five categories: a) Top 10 IP Judgements/Orders (Topicality/Impact) b) Top 10 IP Judgements/Orders (Jurisprudence/Legal Lucidity) c) Top 10 IP Legislative and Policy Related Developments d) Other IP Developments; and e) Other Notable Developments. RDB and Co.

IP 124

IP Copyright Trademark Intellectual Property 124